Deal Roundup: GHO, Ampersand seal $1.1bn Avid Biosciences deal, Mutares makes 15th acquisition of 2024

GHO Capital Partners and Ampersand Capital Partners have agreed to buy biologics CDMO Avid Biosciences in a $1.1bn deal.